# EDGAR Filing Document

**Accession Number:** 0001502152
**File Stem:** 0001161697-23-000103
**Filing Date:** 2023-2
**Character Count:** 65494
**Document Hash:** d615824d9f07b84dae1d909ba464e8d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001161697-23-000103.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001161697-23-000103

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 44

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GlobeStar Therapeutics Corp
- **CENTRAL INDEX KEY:** 0001502152
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 273480481
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55072
- **FILM NUMBER:** 23619920

**BUSINESS ADDRESS:**
- **STREET 1:** 719 JADWIN AVENUE
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99352
- **BUSINESS PHONE:** 509-531-1671

**MAIL ADDRESS:**
- **STREET 1:** 719 JADWIN AVENUE
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99352

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AngioSoma, Inc.
- **DATE OF NAME CHANGE:** 20160622

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** First Titan Corp.
- **DATE OF NAME CHANGE:** 20100927

?xml version="1.0" encoding="utf-8"?

*[**Table of Contents**](#toc)*

**UNITED STATES**

**SECURITY AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

____________________

**FORM 10-Q**

____________________

(MARK ONE)

**☒** **&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2022**

or

**☐** **&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _________ to _________**

Commission File Number: **333-170315**

**<u>GlobeStar Therapeutics Corporation</u>**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **<u>Wyoming</u>** | **<u>27-3480481</u>** |
| (State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification Number) |
| **719 Jadwin Avenue, Richland, WA** | **<u>99352</u>** |
| (Address of principal executive offices) | (Zip code) |

---

Registrant's telephone number, including area code**: 206-451-1970**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☐ <br> (Do not check is smaller reporting company) Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act: None.

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol</u>** | **<u>Name of each exchange on which registered</u>** |
| Common | GSTC | N/A |

---

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of February 9, 2023, 770,360,616 shares of common stock issued and outstanding.

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **[PART I — FINANCIAL INFORMATION](#part1)** | 4 |
| [Item 1. Financial Statements](#item1_01) | 4 |
| *[Consolidated Balance Sheets as of December 31, 2022 (Unaudited) and September 30, 2022](#bs)* | 4 |
| *[Consolidated Statements of Operations for the Three Months Ended December 31, 2022 and 2021 (Unaudited)](#so)* | 5 |
| *[Consolidated Statements of Stockholders' Deficit for the Three Months Ended December 31, 2022 and 2021 (Unaudited)](#eq)* | 6 |
| *[Consolidated Statements of Cash Flows for the Three Months Ended December 31, 2022 and 2021 (Unaudited)](#cf)* | 7 |
| *[Notes to the Unaudited Consolidated Financial Statements](#notes)* | 8 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#item1_02) | 14 |
| [Item 3. Quantitative and Qualitative Disclosures about Market Risk](#item1_03) | 16 |
| [Item 4. Controls and Procedures](#item1_04) | 16 |
| **[PART II — OTHER INFORMATION](#part2)** | 17 |
| [Item 1. Legal Proceedings](#item2_01) | 17 |
| [Item 1A. Risk Factors](#item2_1a) | 17 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#item2_2) | 17 |
| [Item 3. Defaults upon Senior Securities](#item2_3) | 17 |
| [Item 4. Mine Safety Disclosures](#item2_4) | 17 |
| [Item 5. Other Information](#item2_5) | 17 |
| [Item 6. Exhibits](#item2_6) | 18 |
| **[SIGNATURES](#signtures)** | 19 |

---

------

*[**Table of Contents**](#toc)*

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION**

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as "plan", "anticipate", "believe", "estimate", "should", "expect" and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2022. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the "SEC"), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

**OTHER PERTINENT INFORMATION**

When used in this report, the terms, "we," the "Company," "our," and "us" refers to GlobeStar Therapeutics Corporation, a Wyoming corporation and its subsidiaries unless the context specifically indicates otherwise.

------

*[**Table of Contents**](#toc)*

**PART I — FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**GLOBESTAR THERAPEUTICS CORPORATION**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2022** | **September 30,**<br>**2022** |
|  | **(unaudited)** | |
| CURRENT ASSETS |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $7723 | $6365 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 2500 | 3550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 10223 | 9915 |
| TOTAL ASSETS | $10223 | $9915 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT |  |  |
| &nbsp;&nbsp;&nbsp;Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $417001 | $380735 |
| &nbsp;&nbsp;&nbsp;Accounts payable to related party | 440106 | 379126 |
| &nbsp;&nbsp;&nbsp;Related party advances | 12900 | 12400 |
| &nbsp;&nbsp;&nbsp;Advances payable | 59650 | 59650 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of convertible notes payable | 20000 | 20000 |
| &nbsp;&nbsp;&nbsp;Series G Preferred Stock Liability, net of discount of $10,863 and $12,581, respectively | 74387 | 126294 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable | 223745 | 226270 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1247789 | 1204475 |
| TOTAL LIABILITIES | 1247789 | 1204475 |
| COMMITMENTS AND CONTINGENCIES |  |  |
| STOCKHOLDERS' DEFICIT |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, unlimited shares authorized; 770,360,616 and 722,326,669 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively | 770359 | 722325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock; 20,000,000 shares authorized: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Series D Preferred Stock, $0.001 par value; 509,988 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively | 510 | 510 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series E Preferred Stock, $0.001 par value; 1,000,000 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively | 1000 | 1000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series F Preferred Stock; $0.001 par value; 128,991 and 128,991 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively | 129 | 129 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 16651121 | 16581252 |
| &nbsp;&nbsp;&nbsp;Stock payable, consisting of 3,030,304 and 1,515,152 shares to be issued at December 31, 2022 and September 30, 2022, respectively | 10000 | 5000 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (18670685) | (18504776) |
| TOTAL STOCKHOLDERS' DEFICIT | (1237566) | (1194560) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $10223 | $9915 |

---

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

------

*[**Table of Contents**](#toc)*

**GLOBESTAR THERAPEUTICS CORPORATION**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| OPERATING EXPENSES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | $155241 | $166294 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 155241 | 166294 |
| LOSS FROM OPERATIONS | (155241) | (166294) |
| OTHER EXPENSE |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on settlement of liabilities |  | (146460) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (10668) | (20087) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense | (10668) | (166547) |
| Net loss | $(165909) | $(332841) |
| Net loss per common share | $(0.00) | $(0.00) |
| Weighted average shares outstanding - basic and diluted | 755602522 | 573434634 |

---

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

------

*[**Table of Contents**](#toc)*

**GLOBESTAR THERAPEUTICS CORPORATION**

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(UNAUDITED)**

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **Series A** | **Series A** | **Series D** | **Series D** | **Series E** | **Series E** | **Series F** | **Series F** | | | | |
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | | | | |
|  | **Shares** | **Par** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Original**<br>**Additional**<br>**Paid-in**<br>**Capital** |<br>**Stock**<br>**Payable** |<br>**Accumulated**<br>**Deficit** |<br>**Total**<br>**Equity**<br>**(Deficit)** |
| Balance,<br> September 30, 2021 | 561495726 | $561494 |  | $— | 509988 | $510 | 1000000 | $1000 | 386975 | $387 | $15228254 | $499500 | $(17016966) | $(725821) |
| Conversion of Series F Preferred Stock to common | 12899100 | 12899 |  |  |  |  |  |  | (128991) | (129) | (12770) |  |  |  |
| Common stock issued for stock payable | 19980000 | 19980 |  |  |  |  |  |  |  |  | 479520 | (499500) |  |  |
| Common stock issued for settlement of liability | 6000000 | 6000 |  |  |  |  |  |  |  |  | 155460 |  |  | 161460 |
| Net loss for the three months ended December 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  | (332841) | (332841) |
| Balance,<br> December 31, 2021 | 600374826 | $600376 |  | $— | 509988 | $510 | 1000000 | $1000 | 257984 | $258 | $15850464 | $— | $(17349807) | $(897202) |
| Balance,<br> September 30, 2022 | 722326669 | $722325 |  | $— | 509988 | $510 | 1000000 | $1000 | 128991 | $129 | $16581252 | $5000 | $(18504776) | $(1194560) |
| Common stock subscribed for cash proceeds |  |  |  |  |  |  |  |  |  |  |  | 5000 |  | 5000 |
| Conversion of Series G Preferred Stock to common stock | 480333947 | 48034 |  |  |  |  |  |  |  |  | 52066 |  |  | 100100 |
| Stock-based compensation, related parties |  |  |  |  |  |  |  |  |  |  | 17803 |  |  | 17803 |
| Net loss for the three months ended December 31, 2022 |  |  |  |  |  |  |  |  |  |  |  |  | (165909) | (165909) |
| Balance,<br> December 31, 2022 | 770360616 | $770359 |  | $— | 509988 | $510 | 1000000 | $1000 | 128991 | $129 | $16651121 | $10000 | $(18670685) | $(1237566) |

---

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

------

*[**Table of Contents**](#toc)*

**GLOBESTAR THERAPEUTICS CORPORATION**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| CASH FLOW FROM OPERATING ACTIVITIES: |  |  |
| Net loss | $(165909) | $(332841) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Stock compensation, related parties | 17803 |  |
| &nbsp;&nbsp;Amortization of discount on convertible note payable | 9343 | 15753 |
| &nbsp;&nbsp;Loss on settlement of liabilities |  | 146460 |
| Changes in operating assets and liabilities |  |  |
| &nbsp;&nbsp;Prepaid expenses | 1050 | (3750) |
| &nbsp;&nbsp;Accounts payable and accrued liabilities | 36266 | (1491) |
| &nbsp;&nbsp;Accounts payable and accrued liabilities to related party | 60980 | 42000 |
| &nbsp;&nbsp;Accrued interest payable | 1325 | 4334 |
| NET CASH USED IN OPERATING ACTIVITIES | (39142) | (129535) |
| CASH FLOWS FROM FINANCING ACTIVITIES |  |  |
| &nbsp;&nbsp;Proceeds from sale of Series G Preferred Stock | 35000 | 145000 |
| &nbsp;&nbsp;Proceeds from related party advances | 500 |  |
| &nbsp;&nbsp;Proceeds from common stock subscribed | 5000 |  |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 40500 | 145000 |
| NET INCREASE IN CASH | 1358 | 15465 |
| Cash at beginning of period | 6365 | 5960 |
| Cash at end of period | $7723 | $21425 |
| Cash paid during the period for: |  |  |
| &nbsp;&nbsp;Interest | $— | $— |
| &nbsp;&nbsp;Taxes | $— | $— |
| Noncash investing and financing transactions: |  |  |
| &nbsp;&nbsp;Conversion of Series F preferred stock | $— | $12889 |
| &nbsp;&nbsp;Conversion of Series G preferred stock and accrued dividends | $96250 | $— |
| &nbsp;&nbsp;Common stock issued for stock payable | $— | $499500 |
| &nbsp;&nbsp;Common stock issued for settlement of liabilities | $— | $15000 |

---

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

------

*[**Table of Contents**](#toc)*

**GLOBESTAR THERAPEUTICS CORPORATION**

**NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

**December 31, 2022**

**(Unaudited)**

**Note 1. General Organization and Business**

GlobeStar Therapeutics Corporation (the "Company") was incorporated on April 29, 2016. The Company's year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 6.

**Note 2. Going Concern and Summary of Significant Accounting Policies**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the three months ended December 31, 2022, the Company had a net loss of $165,909 and cash flow used in operating activities of $39,142. As of December 31, 2022, the Company had negative working capital of $1,237,566. Management does not anticipate having positive cash flow from operations in the near future. The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business.

These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

Management has plans to address the Company's financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company's ability to continue as a going concern.

In the long term, management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

**Interim Financial Statements**

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2022 which are included on our Form 10-K filed on January 9, 2023. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the three months ended December 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2023.

**Consolidated Financial Statements**

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

------

*[**Table of Contents**](#toc)*

**Recently Issued Accounting Pronouncements**

We have reviewed the FASB issued Accounting Standards Update ("ASU") accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

**Note 3. Convertible Notes Payable**

Convertible notes payable consisted of the following at December 31, 2022 and September 30, 2022:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2022** | **September 30,<br> 2022** |
| Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $0.01 per share. | $20000 | $20000 |
| Total current convertible notes payable, net of discount | $20000 | $20000 |

---

All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company.

As of December 31, 2022 and September 30, 2022, accrued interest on convertible notes payable was $222,287.

**Advances**

As of December 31, 2022 and September 30, 2022, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.

**Note 4. Related Party Transactions**

As of December 31, 2022 and 2022, the Company owed $440,106 and $379,126 to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, the Company received short term, unsecured, non-interest bearing advances from the Company's CEO totaling $500. As of December 31, 2022, the Company owed $12,900 on these related party advances.

In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior three years.

The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $0.009 per share, an exercise term of five years. The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $284,840. During the three months ended December 31, 2022, the Company recognized $17,803 of stock-based compensation, related to outstanding stock options. At December 31, 2022, the Company had $80,111 of unrecognized expense related to options.

------

*[**Table of Contents**](#toc)*

Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of December 31, 2022, no amounts have been earned or paid.

Mr. Katzroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of December 31, 2022, no amounts have been earned or paid.

**Note 5. Stockholders' Deficit**

**Preferred Stock**

*<u>Series A Preferred Stock</u>* – Our board of directors has designated up to 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of 6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an 8% per annum dividend, payable in additional shares of Series A Preferred Stock. At December 31, 2022 and September 30, 2022, there were no shares of our Series A Preferred Stock outstanding, respectively.

*<u>Series B Preferred Stock</u>* – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of 8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At December 31, 2022 and September 30, 2022, there were no shares of our Series B Preferred Stock outstanding.

*<u>Series C Preferred Stock</u>* – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $0.50 per share. The Series C Preferred Stock has been canceled, and there are no shares of Series C Preferred Stock outstanding as of December 31, 2022 and September 30, 2022.

*<u>Series D Preferred Stock</u>* – On September 21, 2017, our board of directors designated up to 539,988 shares of Series D Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series D Preferred Stock have no voting rights. The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. At December 31, 2022 and September 30, 2022, there were 509,988 shares of Series D Preferred Stock outstanding.

*<u>Series E Preferred Stock</u>* – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company.

At December 31, 2022 and September 30, 2022, there were 1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

*<u>Series F Preferred Stock</u>* – On September 21, 2017, our board of directors designated up to 501,975 shares of Series F Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series F Preferred Stock have no voting rights. The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, 257,984 shares of Series F Preferred Stock was converted into 25,798,400 shares of common stock. At December 31, 2022 and September 30, 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding.

------

*[**Table of Contents**](#toc)*

**Common stock issued for stock payable**

In September 2022, the Company received $5,000 of cash as a subscription for 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. In December 2022, the Company received $5,000 of cash as a subscription for an additional 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. The common shares were not yet issued as of December 31, 2022.

**Common Stock Warrants**

The following table summarizes the stock warrant activity for the three months ended December 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **Warrants** | **Weighted-<br> Average<br> Exercise Price<br> Per Share** |
| Outstanding, September 30, 2022 | 71385152 | $0.02 |
| Granted | 1515152 | 0.01 |
| Exercised |  |  |
| Forfeited |  |  |
| Expired |  |  |
| Outstanding, December 31, 2022 | 72900304 | $0.02 |

---

As of December 31, 2022, the outstanding warrants had an expected remaining life of 2.70 years and have an aggregate intrinsic value of $177,700.

**Common Stock Options**

The Company recognized $17,803 of expense related to the fair value of options vesting during the three months ended December 31, 2022. At December 31, 2022, the Company had $80,111 of unrecognized expenses related to options.

The following table summarizes the stock option activity for the three months ended December 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **Options** | **Weighted-<br> Average<br> Exercise Price<br> Per Share** |
| Outstanding, September 30, 2022 | 105000000 | $0.02 |
| Granted |  | $— |
| Exercised |  | $— |
| Forfeited |  | $— |
| Expired |  | $— |
| Outstanding, December 31, 2022 | 105000000 | $0.02 |

---

As of December 31, 2022, all outstanding options had an expected remaining life of 1.60 years and have an aggregate intrinsic value of $150,500.

**Note 6. Series G Preferred Stock**

On August 11, 2021, our board of directors designated up to 1,000,000 shares of Series G Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement. The Company sold 93,500 shares for net cash proceeds of $81,250 of cash proceeds.

------

*[**Table of Contents**](#toc)*

Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into.

During the three months ended December 31, 2022, the Company sold an aggregate of 42,625 shares of Series G Preferred Stock for net cash proceeds of $35,000. The Company recorded a debt discount of $7,625 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $42,625. The Company amortized $9,343 of discount related to Series G Preferred Stock for the three months ended December 31, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $1,325 of interest on the Series G Preferred Stock and had an accrued interest balance of $1,458 and $3,983 as of December 31, 2022 and September 30, 2022, respectively. During the three months ended December 31, 2022, the holder of the Series G converted 96,250 shares of Series G and $3,850 of dividends into 48,033,947 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized.

As of December 31, 2022 and September 30, 2022, 85,250 and 138,875 shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $74,387 and $126,294, respectively, net of unamortized discount of $10,863 and $12,581, respectively.

**Note 7. License Agreement**

Effective August 23, 2020 the Company's wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of 7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones:

● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.

● 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.

● 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and

● Common shares representing an adjustment to increase 7 to Stand's total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.

● $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

The Company paid no royalties and accrued $10,450 of royalties and late fees during the three months ended December 31, 2022. The Company owes $36,700 of royalties and late fees under this agreement as of December 31, 2022 and $26,250 as of September 30, 2022.

The Company is currently in default of this agreement.

------

*[**Table of Contents**](#toc)*

**Note 8. Commitments**

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the "Consultant"). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company fir a period of five years unless mutually terminated sooner. Concurrently, the Consultant entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares was to be completed by June 30, 2022 but has not yet occurred.

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO's fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.

The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. As of December 31, 2022 and September 30, 2022, the Company owed the consultant $137,500 and $100,000, respectively, included in accounts payable and

------

*[**Table of Contents**](#toc)*

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Overview**

GlobeStar Therapeutics Corporation (the "Company") was incorporated on April 29, 2016. The Company's year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

We changed our name to GlobeStar Therapeutics Corporation on April 27, 2021 to better reflect our expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases.

GlobeStar Therapeutics Corporation, based in Richland Washington, is a clinical stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. GlobeStar Therapeutics owns the exclusive global license from the inventors, who are based in Italy. GlobeStar Therapeutics is initiating discussions with the FDA on clinical trial design in preparation for FDA submission and approval pathway.

Prior to the Company's current business plan, the Company was a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals<sup>TM</sup>.

**Professional Team**

We have adopted a Medical Advisory Board and appointed medical doctors and medical professionals that have extensive education and hands on experience with pharmaceutical and nutraceutical solution for prevention and treatment of disease.

**Management's Plan to Attract Capital**

In the near term, management will utilize equity and debt financing to complete assembling the professional and management team to commence the process for clinical trials in compliance with FDA protocol. plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company's ability to continue as a going concern.

In the midterm, management will enhance its capital position with a public offering of equity securities to finance clinical trials and the necessary actions to obtain approval of worldwide marketing of our MS treatment.

In the long term, marketing the Company's pharmaceutical and nutraceutical products will provide the necessary cash flow to support future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of capital to support near term and midterm business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to support its operations.

**Corporate Governance**

We have adopted codes and committees for governance of the corporation that include: (i) audit committee charter, (ii) written acknowledgement of code of ethics for directors and senior officers, (iii) compensation committee charter, (iv) confidential information policy, iv) corporate governance guidelines, (vi) executive committee charter, and (vii) nominating committee charter.

**Critical Accounting Policies**

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the consolidated financial statements are prepared. We regularly review our accounting policies, and how they are applied and disclosed in our consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

------

*[**Table of Contents**](#toc)*

**Results of Operations**

***Three Months Ended December 31, 2022 Compared to the Three Months Ended December 31, 2021***

***Revenue.*** We had no revenue for the three months ended December 31, 2022 and 2021.

***Cost of goods sold.*** We had no cost of goods sold for the three months ended December 31, 2022 and 2021.

***General and administrative expense.*** We recognized general and administrative expense of $155,241 for the three months ended December 31, 2022 compared to $166,294 for the comparable period of 2021. The decrease in general and administrative expense was related decreases in professional expenses along with advertising and marketing, which were offset with an increase in stock-based compensation in the three months ended December 31, 2022 related to options issued to an officer and increased consulting expense in the current period.

***Loss on settlement of liabilities.*** We recognized $0 and $146,460 loss on the settlement of liabilities during the three months ended December 31, 2022 and 2021. The loss was related to the severance agreement with Alex Blankenship, our former CEO.

***Interest expense.*** We recognized interest expense of $10,668 for the three months ended December 31, 2022 compared to $20,087 for the comparable period of 2021, including amortization of the discount on Series G Preferred Stock liability of $9,343 and $15,753 during the three months ended December 31, 2022 and 2021, respectively.

***Net loss.*** For the reasons above, we recognized a net loss of $165,909 for the three months ended December 31, 2022 compared to $332,841 for the three months ended December 31, 2021.

**Liquidity and Capital Resources**

At December 31, 2022, we had cash on hand of $7,723. The Company has negative working capital of $1,237,566. Net cash used in operating activities for the three months ended December 31, 2022 was $39,142. Cash on hand is not adequate to fund our operations for less than twelve months. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to the Company. We have no material commitments for capital expenditures as of December 31, 2022.

During the three months ended December 31, 2022, the net loss of $165,909 was offset by the following non-cash operating expenses: stock compensation, related parties of $17,803, amortization of discount of $9,343 resulting in cash flows used in operating activities of $39,142. The Company had cash flows from financing activities of $40,500, primarily due to $35,000 from the proceeds of sale of Series G Preferred Stock, $5,000 in proceeds from the common stock subscribed and $500 of related party advances.

**Additional Financing**

Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

**Off Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

------

*[**Table of Contents**](#toc)*

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable to a smaller reporting company.

**ITEM 4. CONTROLS AND PROCEDURES**

**Management's Report on Internal Control over Financial Reporting**

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

1. As of December 31, 2022, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees our accounting policies and procedures. This has resulted in inconsistent practices. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2. As of December 31, 2022, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

Our management, including our principal executive officer and principal financial officer do not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

**Change in Internal Controls Over Financial Reporting**

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

------

*[**Table of Contents**](#toc)*

**PART II — OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

**ITEM 1A. RISK FACTORS**

Not applicable to a smaller reporting company.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

Set forth below is information regarding the securities sold during the quarter ended December 31, 2022 that were not registered under the Securities Act:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Date of Sale** | **Title of<br> Security** | **Number<br> Sold** | **Consideration Received**<br> **and Description of**<br> **Underwriting or Other**<br> **Discounts to Market**<br> **Price or Convertible**<br> **Security, Afforded to**<br> **Purchasers** | **Exemption from**<br> **Registration**<br> **Claimed** | **If Option,<br> Warrant or<br> Convertible**<br> **Security, terms <br> of exercise<br> or conversion** |
| October 4, 2022 | Common Stock | 7090909 | Conversion of Series G Preferred Stock | Section 3(a)(9) of the Securities Act | $0.0022 |
| October 13, 2022 | Common Stock | 7090909 | Conversion of Series G Preferred Stock | Section 3(a)(9) of the Securities Act | $0.0022 |
| October 18, 2022 | Common Stock | 8976190 | Conversion of Series G Preferred Stock | Section 3(a)(9) of the Securities Act | $0.0021 |
| November 10, 2022 | Common Stock | 10947368 | Conversion of Series G Preferred Stock | Section 3(a)(9) of the Securities Act | $0.0019 |
| November 14, 2022 | Common Stock | 13928571 | Conversion of Series G Preferred Stock | Section 3(a)(9) of the Securities Act | $0.0021 |

---

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

The Company has not defaulted upon senior securities.

**ITEM 4. MINE SAFETY DISCLOSURES**

This item is not applicable.

**ITEM 5. OTHER INFORMATION**

None.

------

*[**Table of Contents**](#toc)*

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| 3.1 | [Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1502152/000116169715000162/def14a.htm) (1) |
| 3.2 | [Bylaws](http://www.sec.gov/Archives/edgar/data/1502152/000116169716000635/ex_3-2.htm) (2) |
| 14.1 | [Code of Ethics](http://www.sec.gov/Archives/edgar/data/1502152/000116169710001010/ex_14-1.htm) (3) |
| 31.1 | [Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer](ex_31-1.htm) (4) |
| 31.2 | [Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer](ex_31-2.htm) (4) |
| 32.1 | [Section 1350 Certification of principal executive officer](ex_32-1.htm) (4) |
| 32.2 | [Section 1350 Certification of principal financial officer](ex_32-2.htm) (4) |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. (5) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document (5) |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (5) |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (5) |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (5) |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) (5) |

---

__________

(1) Incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on April 8, 2015.

(2) Incorporated by reference to our Form 10-K/A Amendment No. 1 for the year ended September 30, 2015 filed on January 22, 2016.

(3) Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on November 3, 2010.

(4) Filed or furnished herewith.

(5) In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q
shall be deemed "furnished" and not "filed."

------

*[**Table of Contents**](#toc)*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | **GlobeStar Therapeutics Corporation** |
| Date: February 13, 2023 | By: /s/ James C. Katzaroff |
|  | James C. Katzaroff |
|  | Chief Executive Officer, President, Secretary, Principal Executive Officer and Director |
| Date: February 13, 2023 | By: /s/ Robert Chicoski |
|  | Robert Chicoski |
|  | Chief Financial Officer, Treasurer, Secretary, Principal Financial and Accounting Officer |

---

------

## Ex-31

**Exhibit 31.1**

**RULE 13A-14(A)/15D-14(A) CERTIFICATION**

I, James C. Katzaroff, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2022 of GlobeStar Therapeutics Corporation.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 13, 2023 | By: /s/ James C. Katzaroff |
|  | James C. Katzaroff |
|  | Chief Executive Officer |

---

------

## Ex-31

**Exhibit 31.2**

**RULE 13A-14(A)/15D-14(A) CERTIFICATION**

I, Robert Chicoski, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2022 of GlobeStar Therapeutics Corporation.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 13, 2023 | By: /s/ Robert Chicoski |
|  | Robert Chicoski |
|  | Chief Financial Officer |

---

------

## Ex-32

**Exhibit 32.1**

**SECTION 1350 CERTIFICATION**

In connection with the quarterly report of GlobeStar Therapeutics Corporation (the "Company") on Form 10-Q for the period ended December 31, 2022 as filed with the Securities and Exchange Commission (the "Report"), I, James C. Katzaroff, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of
 Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents,
 in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| Date: February 13, 2023 | By: /s/ James C. Katzaroff |
|  | James C. Katzaroff |
|  | Chief Executive Officer |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Ex-32

**Exhibit 32.2**

**SECTION 1350 CERTIFICATION**

In connection with the quarterly report of GlobeStar Therapeutics Corporation (the "Company") on Form 10-Q for the period ended December 31, 2022 as filed with the Securities and Exchange Commission (the "Report"), I, Robert Chicoski, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of
 Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents,
 in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| Date: February 13, 2023 | By: /s/ Robert Chicoski |
|  | Robert Chicoski |
|  | Chief Financial Officer |

---

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

------